Loading
Ropeginterferon alfa-2b is a long-acting interferon for polycythaemia vera that, unlike hydroxyurea, can shrink the mutant clone over years.
Ropeginterferon alfa-2b is a mono-pegylated, long-acting interferon alfa given every two weeks. Type I interferon signalling preferentially suppresses the JAK2-mutant clone in polycythaemia vera, with antiproliferative and immunomodulatory effects that hydroxyurea does not share. In PROUD-PV and its CONTINUATION-PV extension, complete haematological response and JAK2 allele-burden reduction were superior to hydroxyurea by 3 to 6 years, and Low-PV showed benefit in low-risk patients who would otherwise receive phlebotomy alone. It was the first interferon approved specifically for PV, in the EU in 2019 and the US in 2021. Depression, autoimmunity and flu-like symptoms need monitoring, and whether clone reduction means fewer transformations is still being followed. In short, this is the PV drug that can shrink the mutant clone over years rather than just control blood counts.
Backbone ribbon from PDB 1RH2. RCSB PDB 1RH2. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
The N-terminal proline and PEG chain are not shown.
Type I interferon signalling suppresses the JAK2-mutant clone preferentially, with immunomodulatory and antiproliferative effects; every-2-week dosing. Connects to JAK2.
1.Ropeginterferon alfa-2b binds JAK2.
Subcutaneous injection every two weeks; when administered in the clinic it is billed under Part B, and the label permits self-injection after training, in which case Part D plans may cover it. Confirm which benefit the plan applies.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Polycythaemia vera; some plans require hydroxyurea intolerance or failure first.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: ropeginterferon alfa-2b. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2019 | Polycythaemia vera without symptomatic splenomegaly |
| US | 2021 | Polycythaemia vera |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ropeginterferon alfa-2b" OR ABSTRACT:"Ropeginterferon alfa-2b" OR TITLE:"Besremi" OR ABSTRACT:"Besremi") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ropeginterferon alfa-2b, not a curated reading list.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV), Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Aquagenic pruritus, JAK2 V617F, Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission, Essential thrombocythaemia (ET).
Shares PROUD-PV and CONTINUATION-PV, Essential thrombocythaemia (ET), Polycythaemia vera (PV), Primary myelofibrosis.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV), JAK2, Primary myelofibrosis.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV), Primary myelofibrosis, Cytokines & engineered cytokines.
Shares Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance, Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Low-PV, Polycythaemia vera (PV).
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV), Primary myelofibrosis.